About Epoxide hydrolase 4
Epoxide hydrolase 4 (EPHX4) is a protein
from Homo sapiens identified by UniProt accession
Q8IUS5, 362 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Epoxide hydrolase 4 |
|---|
| UniProt accession | Q8IUS5 |
|---|
| Gene | EPHX4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 362 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (41)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- HbA1c measurement · score 0.09
- lymphocyte percentage of leukocytes · score 0.07
- smoking status measurement · score 0.07
- laryngeal squamous cell carcinoma · score 0.06
- colorectal adenocarcinoma · score 0.05
- mean corpuscular hemoglobin concentration · score 0.05
- neutrophil percentage of leukocytes · score 0.05
- hepatocellular carcinoma · score 0.04
- monocyte count · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IUS5-F1 | alphafold | PREDICTED | 93.01 | — |
Amino-acid sequence (362 residues)
MARLRDCLPR LMLTLRSLLF WSLVYCYCGL CASIHLLKLL WSLGKGPAQT FRRPAREHPP ACLSDPSLGT HCYVRIKDSG LRFHYVAAGE RGKPLMLLLH GFPEFWYSWR YQLREFKSEY RVVALDLRGY GETDAPIHRQ NYKLDCLITD IKDILDSLGY SKCVLIGHDW GGMIAWLIAI CYPEMVMKLI VINFPHPNVF TEYILRHPAQ LLKSSYYYFF QIPWFPEFMF SINDFKVLKH LFTSHSTGIG RKGCQLTTED LEAYIYVFSQ PGALSGPINH YRNIFSCLPL KHHMVTTPTL LLWGENDAFM EVEMAEVTKI YVKNYFRLTI LSEASHWLQQ DQPDIVNKLI WTFLKEETRK KD
Explore Epoxide hydrolase 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets